Pharma BD Deal Intelligence
AstraZeneca taps Merck in $8.5B cancer deal to co-develop and co-commercialize Lynparza both as monotherapy and in combination with their respective PD-L1 and…
AstraZeneca and Merck enter an $8.5 billion oncology collaboration combining Lynparza with each company's immuno-oncology assets, reflecting the growing…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Merck and AstraZeneca formed a global strategic oncology collaboration to co-develop and co-commercialize Lynparza (olaparib) and selumetinib. Merck paid $1.6B upfront plus $750M for license options, with up to $6.15B in regulatory and sales milestones. The companies share development costs and profits for both solo and combination therapies with their respective PD-1/PD-L1 agents.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / AstraZeneca PLC (this deal) | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2017 deals · Merck & Co. Inc. deals · Oncology deals